ImaRx Therapeutics' urokinase gains an additional 20 months of expiration dating
ImaRx Therapeutics' urokinase has received an additional 20 months of expiration dating. This means the clot buster from the Tucson, Ariz., firm's most recent lot will have a prolonged shelf life. The thombolytic is indicated for the treatment of acute massive pulmonary embolism.
To see more Daily News articles, click here.
To go to the Drug Topics homepage, clickhere.